Angiopoietin-2, its soluble receptor Tie-2 and subclinical cardiovascular disease in a population-based sample

Lorbeer, Roberto; Baumeister, Sebastian E.; Dörr, Marcus; Felix, Stephan B.; Nauck, Matthias; Grotevendt, Anne; Markus, Marcello Ricardo Paulista; Sarnowski, Bettina von; Völzke, Henry; Vasan, Ramachandran S.; Wallaschofski, Henri; Lieb, Wolfgang

doi:10.1136/heartjnl-2014-306056

Cited by 21 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…investigated the correlation between Angpt2 and the index of cardiac function impairment and showed that Angpt2 level was significantly correlated with the severity of congestive heart failure18. The study of Health in Pomerania (SHIP) that included 3204 normal subjects with a median age of 55 years to evaluate the relationship between Ang-2 and cardiac function revealed that high circulating Angpt2 level was associated with low LVFS value as a measure of LV systolic function, but not with LVMI as a measure of LV structure19. However, the information between Angpt2 and associated markers of angiogenesis and actual cardiac structure and function status is limited in CKD population.…”

Section: Discussionmentioning

confidence: 99%

Angiopoietin-2, Angiopoietin-1 and subclinical cardiovascular disease in Chronic Kidney Disease

Tsai

Lee

Chiu

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Angiopoietins (Angpt) and vascular endothelial growth factor (VEGF) have been associated with cardiovascular disease. The study enrolled 270 pre-dialysis stage 3–5 CKD patients to assess the link between circulating Angpt2, Angpt1 and VEGF-A and subclinical measures of cardiovascular structure and function. Serum markers of angiogenesis were measured using commercial enzyme-linked immunosorbent assays. Cardiac structure and function were examined by echocardiography. Brachial-ankle pulse wave velocity (baPWV) was measured by the ankle-brachial index. The adjusted mean of left ventricular mass index (LVMI) was 2.05 in patients of Angpt2 quartile 4 and 1.99 in those of Angpt2 quartile 1 (P = 0.04). Angpt2 was significantly associated with LV hypertrophy (LVH) (Angpt2 quartile 4 compared with Angpt2 quartile 1: adjusted OR: 2.68, 95% CI: 1.15–6.20). Angpt1 was negatively correlated with left atrial diameter (adjusted mean of LAD: 3.59 in Angpt1 quartile 4, 3.92 in Angpt1 quartile 1, P = 0.03). A positive and significant correlation was found between Angpt2 level and baPWV in spearman’s correlation, but not in adjusted model. In conclusion, high Angpt2 and low Angpt1 levels were positively associated with abnormal cardiac structure in stages 3–5 CKD patients, which is compatible with the viewpoint that angiopoietins participates in cardiovascular burdens.

show abstract

Section: Discussionmentioning

confidence: 99%

Angiopoietin-2, Angiopoietin-1 and subclinical cardiovascular disease in Chronic Kidney Disease

Tsai

Lee

Chiu

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In addition, serum Angpt2 levels has been correlated with subclinical cardiovascular diseases such as fractional shortening, number of carotid plaques [21] and carotid intima media thickness [22]. In our previous reports, we found that CKD patients with high serum Angpt2 levels were more likely to have high brachial-ankle pulse wave velocity, high left ventricular mass index and left ventricular hypertrophy [23].…”

Section: Discussionmentioning

confidence: 99%

Angiopoietin-2, Renal Deterioration, Major Adverse Cardiovascular Events and All-Cause Mortality in Patients with Diabetic Nephropathy

Tsai¹,

Lee²,

Chiu³

et al. 2018

Kidney Blood Press Res

View full text Add to dashboard Cite

Background/Aims: Diabetic nephropathy is the leading cause of end-stage renal disease and accounts for 30∼40% of patients requiring maintenance dialysis, thereby increasing the burden on health insurance programs. Diabetic nephropathy is also the strongest predictor of cardiovascular morbidity and mortality. The aim of this study was to examine whether angiopoietin-2 (Angpt2), a modulator of endothelial function, affects the clinical outcomes of diabetic patients. Methods: This study enrolled 236 patients with diabetes mellitus with estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m² from January 2006 to December 2011, who were followed until June 2017. Clinical outcomes included renal outcomes (commencing dialysis and rapid decline in renal function (eGFR decline > 3 ml/min per 1.73 m²/year)), major adverse cardiovascular events (MACEs), and all-cause mortality. Results: Over a mean follow-up period of 3.9±2.7 years, 135 (57.2%) patients commenced dialysis, 106 (44.9%) had rapid decline in renal function, and 50 (21.2%) had MACEs or died from all-causes. Log-formed Angpt2 was significantly associated with increased risks of commencing dialysis (HR: 3.91, 95% CI: 1.56-9.76), rapid renal function decline (OR: 6.81, 95% CI: 1.06-43.88), and MACEs or all-cause mortality (HR: 6.34, 95% CI: 1.18-33.97) in the adjusted analysis. Patients in the highest quartile had hazard ratios of 2.90 and 3.11 for commencing dialysis and rapid renal function decline, respectively, compared to those in the lowest quartile after adjustments. Similar significant dose-response results were found in composite outcomes of either MACEs or all-cause mortality. Conclusion: Angpt2 is an independent predictor of adverse clinical outcomes in diabetic patients. Further studies are needed to identify the pathogenic role of Angpt2 in renal deterioration and cardiovascular complications of diabetes mellitus.

show abstract

“…In contrast, in our study, we considered the changes of Ang-2, which take into account the baseline value for each individual patient. It is especially important, since patients with cardiovascular disease, cerebrovascular disease or hypertension are more likely to have higher circulating Ang-2 levels [26–28]. However, based on our data absolute values and the kinetics of change are individual specific.…”

Section: Discussionmentioning

confidence: 79%

Systemic Angiopoietin-1/2 Dysregulation Following Cardiopulmonary Bypass in Adults

Charbonney

Wilcox

Shan³

et al. 2017

Future Sci. OA

View full text Add to dashboard Cite

Aim:Vascular leakage following cardiopulmonary bypass contributes to morbidity. Angiopoietin-1 and -2 are biomarkers of endothelial dysfunction. Our aim was to characterize Ang-1 and -2 association with clinical characteristics and outcomes.Methods:Observational cohort study measuring Ang-1/-2 with a panel of cytokines in adults undergoing cardiopulmonary bypass.Results:Ang-2 levels increased immediately postop whereas Ang-1 levels decreased over time. No significant correlation was found with other inflammatory mediators. High correlation was found between the hospital length of stay and Ang-2 increase at 24 h (rho = 0.590; p < 0.0001). The predictors of Ang-2 increase were female gender, cross clamp time, transfusion of blood and absence of angiotensin-converting enzyme inhibitor as a pre-op medication.Conclusion:Angiopoietins can detect vascular leakage early and could impact patient's management to decrease length of stay after cardiac surgery.

show abstract

Angiopoietin-2, its soluble receptor Tie-2 and subclinical cardiovascular disease in a population-based sample

Abstract: Circulating Ang-2 levels were associated with select subclinical cardiovascular disease traits, consistent with the notion that the Ang-2-pathway plays a role in mediating cardiovascular morbidity.

Cited by 21 publications

References 28 publications

Angiopoietin-2, Angiopoietin-1 and subclinical cardiovascular disease in Chronic Kidney Disease

Angiopoietin-2, Angiopoietin-1 and subclinical cardiovascular disease in Chronic Kidney Disease

Angiopoietin-2, Renal Deterioration, Major Adverse Cardiovascular Events and All-Cause Mortality in Patients with Diabetic Nephropathy

Systemic Angiopoietin-1/2 Dysregulation Following Cardiopulmonary Bypass in Adults

Contact Info

Product

Resources

About